Lifeboat Foundation

Lincoln Cannon asked me to do a talk a few months ago for the MTA. It was a good time. I learned a lot from the other speakers. Bryan Johnson opened the event and it was interesting to learn about his path and vision for the future. I would like to see many more people in his position. My goal is to make many millionaires out of biotech visionaries through the BioViva platform so that they can reinvest into great tech. Thanks, Lincoln and Bryan!

At the 2018 Conference of the Mormon Transhumanist Association, held 7 Apr 2018 at the Marriott Hotel and Conference Center in Provo, UT, speakers addressed the themes of Mormonism, Transhumanism and Transfigurism, with particular attention to topics at the intersection of technology, spirituality, science and religion. Members, friends and critics of the association have many views. This is one of them. It is not necessarily shared by others.

The effects of donor age on organ transplants: A review and implications for aging research.

Despite the considerable amount of data available on the effect of donor age upon the outcomes of organ transplantation, these still represent an underutilized resource in aging research. In this review, we have compiled relevant studies that analyze the effect of donor age in graft and patient survival following liver, kidney, pancreas, heart, lung and cornea transplantation, with the aim of deriving insights into possible differential aging rates between the different organs. Overall, older donor age is associated with worse outcomes for all the organs studied. Nonetheless, the donor age from which the negative effects upon graft or patient survival starts to be significant varies between organs. In kidney transplantation, this age is within the third decade of life while the data for heart transplantation suggest a significant effect starting from donors over age 40. This threshold was less defined in liver transplantation where it ranges between 30 and 50 years. The results for the pancreas are also suggestive of a detrimental effect starting at a donor age of around 40, although these are mainly derived from simultaneous pancreas-kidney transplantation data. In lung transplantation, a clear effect was only seen for donors over 65, with negative effects of donor age upon transplantation outcomes likely beginning after age 50. Corneal transplants appear to be less affected by donor age as the majority of studies were unable to find any effect of donor age during the first few years posttransplantation. Overall, patterns of the effect of donor age in patient and graft survival were observed for several organ types and placed in the context of knowledge on aging.

Together, Forever Healthy Foundation and SENS Research Foundation are now accepting research proposals that promise progress in regenerative medicine for the prevention and reversal of age-related disease. This Fellowship will take place at SRF’s research center in Mountain View, California.

For more information, please visit: http://sens.org/research/research-blog/forever-healthy-found…technology

A neurological “functional fingerprint” allows scientists to explore the influence of genetics, environment and aging on brain connectivity.

https://www.youtube.com/watch?v=SWjI4Hekaxc

Website ► http://sens.org
YouTube ► https://www.youtube.com/user/SENSFVideo
Facebook ► https://www.facebook.com/sensf
Twitter ► https://twitter.com/senstweet

“At SENS Research Foundation, we believe that a world free of age-related disease is possible. That’s why we’re funding work at universities across the world and at our own Research Center in Mountain View, CA.

Continue reading “Aubrey de Grey — We Will End Aging” »

Today, we would like to share the talk that Steven A. Garan gave at our recent conference in New York, Ending Age-Related Diseases: Investment Prospects & Advances in Research. The conference focused on bringing together the world of research and investment and bringing thought leaders, investors, the media, and the general public together.

Steven A. Garan is the Director of Bioinformatics at the Center for Research and Education on Aging (CREA) and a researcher at UC Berkeley National Laboratory. In his talk at Ending Age-Related Diseases, he discussed the impact of various present and future Silicon Valley technology breakthroughs on overcoming aging.

Continue reading “Steven A. Garan — Silicon Valley’s Role in Fighting Aging” »

To understand how cells in the body behave, bioengineers create miniature models of the cells’ environment in their lab. But recreating this niche environment is incredibly complex in a controlled setting, because researchers are still learning all the factors that influence cell behavior and growth. By observing and then modifying their engineered mini-models, scientists are better able to identify those factors.

This form of cellular research is essential to the study of regenerative medicine, which focuses on replacing or repairing damaged tissue, often through the use of stem cells, a special population of cells that can give rise to all tissues in the body. Bioengineers face the central question of regenerative medicine: what causes stem cells to grow, organize, and mature from a small population of cells to complex organs?

To find an answer, a research team from the Johns Hopkins Institute for NanoBioTechnology borrowed a process commonly used in the electronics industry called micropatterning, in which the miniaturization of shapes increases the number of transistors on a circuit. The team created micropatterned shapes, coupled with machine learning, to see how confinement influences stem cell maturation and organization.

Continue reading “Bioengineers borrow from electronics industry to get stem cells to shape up” »

This is the second part of a short fictional story about a man realizing for the first time that he has a deep desire to avoid aging and death. We published the first part of the story last Friday, and you can read it here.

I feel ashamed admitting to this, but I proceeded with wariness all the way to my door. That late at night, I didn’t meet anyone in the hallways or in the elevator. At first, I didn’t even want to take the elevator, as I was afraid that the girl might suddenly appear before me when the doors opened as I got in or out; however, for some reason, the idea of taking the stairs felt even worse, nearly terrifying. After hesitating some, I chose to take the elevator. Once I reached my door, I inserted the key in the lock, and after a moment of hesitation, I began turning it. At each turn, which echoed sinisterly in the hallway, I stopped as if to check that the sound didn’t attract the attention of God knows what supernatural creatures lurking in the dark. Absolutely nothing looked different than usual, yet I felt like a character in a horror movie.

I opened a crack between the door and the frame, stuck a hand in, and frantically searched for the light switch on the wall. “Finally home,” I said in an annoyed and embarrassingly loud and shaky voice to no one in particular, while still searching for the switch with no success. Once I found it, I flicked it, and as soon as the light went on, I pulled the door wide open, ran in, and finally slammed the door shut behind me.

Kelsey Moody, CEO of Ichor Therapeutics, discusses the creation of a gut-stable antibody mimetic for Parkinson’s disease and announces 10 million dollars in investment from Juvenescence into Ichor portfolio company Antoxerene Inc. at the Ending Age-Related Diseases conference in NYC.

More at: https://www.leafscience.org/ending-age-related-diseases-2018/